BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 17509079)

  • 1. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
    Melino S; Paci M
    FEBS J; 2007 Jun; 274(12):2986-3002. PubMed ID: 17509079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.
    Lescar J; Luo D; Xu T; Sampath A; Lim SP; Canard B; Vasudevan SG
    Antiviral Res; 2008 Nov; 80(2):94-101. PubMed ID: 18674567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The active essential CFNS3d protein complex.
    Melino S; Fucito S; Campagna A; Wrubl F; Gamarnik A; Cicero DO; Paci M
    FEBS J; 2006 Aug; 273(16):3650-62. PubMed ID: 16911516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
    Erbel P; Schiering N; D'Arcy A; Renatus M; Kroemer M; Lim SP; Yin Z; Keller TH; Vasudevan SG; Hommel U
    Nat Struct Mol Biol; 2006 Apr; 13(4):372-3. PubMed ID: 16532006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dengue hemorrhagic fever with special emphasis on immunopathogenesis.
    Kurane I
    Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):329-40. PubMed ID: 17645944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design.
    Murthy HM; Judge K; DeLucas L; Padmanabhan R
    J Mol Biol; 2000 Aug; 301(4):759-67. PubMed ID: 10966782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.
    Lai H; Teramoto T; Padmanabhan R
    Methods Mol Biol; 2014; 1138():345-60. PubMed ID: 24696347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain.
    Arias CF; Preugschat F; Strauss JH
    Virology; 1993 Apr; 193(2):888-99. PubMed ID: 8460492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of NS2B-mediated activation of NS3pro in dengue virus: molecular dynamics simulations and bioassays.
    Zuo Z; Liew OW; Chen G; Chong PC; Lee SH; Chen K; Jiang H; Puah CM; Zhu W
    J Virol; 2009 Jan; 83(2):1060-70. PubMed ID: 18971276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and disulfide bond connectivity-activity studies of a kalata B1-inspired cyclopeptide against dengue NS2B-NS3 protease.
    Gao Y; Cui T; Lam Y
    Bioorg Med Chem; 2010 Feb; 18(3):1331-6. PubMed ID: 20042339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathological mechanisms in dengue and dengue hemorrhagic fever.
    Green S; Rothman A
    Curr Opin Infect Dis; 2006 Oct; 19(5):429-36. PubMed ID: 16940865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the West Nile virus protease substrate specificity and inhibitors.
    Mueller NH; Yon C; Ganesh VK; Padmanabhan R
    Int J Biochem Cell Biol; 2007; 39(3):606-14. PubMed ID: 17188926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue vaccines approach the finish line.
    Edelman R
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S56-60. PubMed ID: 17582571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides.
    Niyomrattanakit P; Yahorava S; Mutule I; Mutulis F; Petrovska R; Prusis P; Katzenmeier G; Wikberg JE
    Biochem J; 2006 Jul; 397(1):203-11. PubMed ID: 16489931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactive T-cell responses to the nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever patients in Malaysia.
    Appanna R; Huat TL; See LL; Tan PL; Vadivelu J; Devi S
    Clin Vaccine Immunol; 2007 Aug; 14(8):969-77. PubMed ID: 17567768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites.
    Chanprapaph S; Saparpakorn P; Sangma C; Niyomrattanakit P; Hannongbua S; Angsuthanasombat C; Katzenmeier G
    Biochem Biophys Res Commun; 2005 May; 330(4):1237-46. PubMed ID: 15823576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study the antiviral activity of some derivatives of tetracycline and non-steroid anti inflammatory drugs towards dengue virus.
    Rothan HA; Buckle MJ; Ammar YA; Mohammadjavad P; Shatrah O; Noorsaadah AR; Rohana Y
    Trop Biomed; 2013 Dec; 30(4):681-90. PubMed ID: 24522138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.
    Lin KH; Ali A; Rusere L; Soumana DI; Kurt Yilmaz N; Schiffer CA
    J Virol; 2017 May; 91(10):. PubMed ID: 28298600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction.
    Wichapong K; Pianwanit S; Sippl W; Kokpol S
    J Mol Recognit; 2010; 23(3):283-300. PubMed ID: 19693793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and docking studies of peptide inhibitors as potential antiviral drugs for dengue virus ns2b/ns3 protease.
    Velmurugan D; Mythily U; Rao K
    Protein Pept Lett; 2014; 21(8):815-27. PubMed ID: 23855663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.